Serum Concentration of Estradiol and Estrone Following Oral Administration of Low-dose Hormone Therapy in Postmenopausal Korean Women
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To determine the baseline serum concentrations of estradiol and estrone in postmenopausal Korean women and the serum concentrations of estradiol and estrone after 4 and 16 weeks of treatment using 1 mg of estradiol and 2 mg of drospirenone. Methods: This was a multicenter study. Thirty-six subjects were screened. Serum estradiol, estrone and drospirenone levels were determined by gas chromatography-mass spectrometry and radioimmunoassay. Results: The mean estradiol concentration was 8.37 ± 12.1 pg/mL at baseline and increased to 53.7 ± 52.1 and 41.4 ± 26.1 pg/mL after 4 and 16 weeks of treatment, respectively. The mean estrone concentrations were 28.7 ± 26.8, 266.1 ± 182.9, and 256.1 ± 179.1 pg/mL at baseline, and after 4 and 16 weeks of treatment, respectively. When women were stratified according to the basal estradiol level, the level after 4 weeks of treatment was significantly higher in the women with a detectable level (≥ 5 pg/mL) than in women with an undetectable level (＜ 5 pg/mL; 65.2 ± 21.5 vs. 37.4 ± 25.8 pg/mL, P = 0.008). After 16 weeks of treatment, the estradiol level was still higher in the detectable group (51.6 ± 28.6 vs. 38.7 ± 21.7 pg/mL, P = 0.09). Conclusion: This study showed that 1 mg of estradiol and 2 mg of drospirenone is an appropriate regimen to achieve the desired serum estradiol level. The difference in serum hormonal levels after 4 weeks of treatment could be caused by different basal levels.
Abstract
Objectives: To determine the baseline serum concentrations of estradiol and estrone in postmenopausal Korean women and the serum concentrations of estradiol and estrone after 4 and 16 weeks of treatment using 1 mg of estradiol and 2 mg of drospirenone. Methods: This was a multicenter study. Thirty-six subjects were screened. Serum estradiol, estrone and drospirenone levels were determined by gas chromatography-mass spectrometry and radioimmunoassay. Results: The mean estradiol concentration was 8.37 ± 12.1 pg/mL at baseline and increased to 53.7 ± 52.1 and 41.4 ± 26.1 pg/mL after 4 and 16 weeks of treatment, respectively. The mean estrone concentrations were 28.7 ± 26.8, 266.1 ± 182.9, and 256.1 ± 179.1 pg/mL at baseline, and after 4 and 16 weeks of treatment, respectively. When women were stratified according to the basal estradiol level, the level after 4 weeks of treatment was significantly higher in the women with a detectable level (≥ 5 pg/mL) than in women with an undetectable level (＜ 5 pg/mL; 65.2 ± 21.5 vs. 37.4 ± 25.8 pg/mL, P = 0.008). After 16 weeks of treatment, the estradiol level was still higher in the detectable group (51.6 ± 28.6 vs. 38.7 ± 21.7 pg/mL, P = 0.09). Conclusion: This study showed that 1 mg of estradiol and 2 mg of drospirenone is an appropriate regimen to achieve the desired serum estradiol level. The difference in serum hormonal levels after 4 weeks of treatment could be caused by different basal levels.
참고문헌 (17)
- Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
- ".Available from" (2006)[URL]
- Toniolo PG, "A prospective study of endogenous estrogens and breast cancer in postmenopausal women", J Natl Cancer Inst, 87, pp.190~197 (1995)
- Archer DF, "Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding", Fertil Steril, 75, pp.1080~1087 (2001)
- Lobo RA, "Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism", Fertil Steril, 76, pp.13~24 (2001)
- Blode H, "A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers", Eur J Contracept Reprod Health Care, 5, pp.256~264 (2000)
- 이병석, "Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal korean women: A double-blind, randomized, placebo-controlled, multicenter study", MATURITAS, 57, pp.361~369
- Judd HL, "Serum androgens and estrogens in postmenopausal women with and without endometrial cancer", Am J Obstet Gynecol, 136, pp.859~871 (1980)
- Verdonck L, "Comparison of quick methods of the estimation of estradiol in plasma by radioimmunoassay", J Steroid Biochem, 5, pp.471~479 (1974)
- Poortman J, "Plasma oestrone, oestradiol and androstenedione levels in post-menopausal women: relation to body weight and height", Maturitas, 3, pp.65~71 (1981)
- Archer DF, "Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial", Menopause, 12, pp.716~727 (2005)
- Schurmann R, "Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens", Climacteric, 7, pp.189~196 (2004)
- Warming L, "Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis", Climacteric, 7, pp.103~111 (2004)
- Anderson AB, "Comparison of serum oestrogen concentrations in post-menopausal women taking oestrone sulphate and oestradiol", Br Med J, 1, pp.140~142 (1978)
- Nichols KC, "17 beta-estradiol for postmenopausal estrogen replacement therapy", Obstet Gynecol Surv, 39, pp.230~245 (1984)
- Kuhl H, "Pharmacokinetics of oestrogens and progestogens", Maturitas, 12, pp.171~197 (1990)
- Fotherby K, "Intrasubject variability in the pharmacokinetics of ethynyloestradiol", J Steroid Biochem Mol Biol, 38, pp.733~736 (1991)